linjc16/ctgov huggingface dataset:
Nonalcoholic Fatty Liver Disease in Taiwanese Children

Study Overview
=================
Brief Summary
-----------------
Nonalcoholic fatty liver disease (NAFLD) is an emerging and important disease in Taiwan. However, the prevalence and clinical characteristics have not been studied well. The purpose of this study is to resolve the aforementioned problem.

Detailed Description
-----------------
[Study Subjects] Obesity was defined as the BMI value > 95 percentile by different age- and gender groups according to the standards of the Department of Health in Taiwan. [Data Collection] The following data were obtained for each subject: age, gender, BMI, waist and hip circumference. BMI was calculated as body weight (kg)/ height (m2). In fasting venous blood samples, we measured total serum bilirubin, alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase, fasting glucose, triglyceride, total cholesterol,high-density lipoprotein cholesterol, insulin, glucose, and adiponectin. [Liver Ultrasonography] All participants underwent an ultrasonographic study of the liver performed by one operator. NAFLD was defined as the presence of an ultrasonographic pattern consistent with the following criteria: liver-kidney echo discrepancy, attenuated echo penetration and visibility of diaphragm, and obscure hepatic vessel structures.

Official Title
-----------------
Prevalence, Clinicopathological Characteristics, Biomarkers and Genetics of Nonalcoholic Steatohepatitis in Taiwanese Children

Conditions
-----------------
Fatty Liver

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of fatty liver Exclusion Criteria: other hepatic diseases

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| non-alcoholic fatty liver disease | confirmed by liver ultrasonography | one year |
Barriers to Efficient PACU Discharge at a Major Academic Orthopaedic Ambulatory Surgery Center

Study Overview
=================
Brief Summary
-----------------
This is a retrospective chart review to determine the etiologies contributing to prolonged PACU discharge at a major Orthopedic Ambulatory Center

Detailed Description
-----------------
Increasing number of surgeries are now performed at ambulatory surgical centers including orthopaedic procedures. While healthier patients usually undergo non-major orthopaedic procedures using regional anesthesia to facilitate faster discharges, prolonged PACU discharges are frequently encountered necessitating characterization and identification of modifiable variables. This is a retrospective chart review to determine the etiologies contributing to prolonged PACU discharge at a major Orthopedic Ambulatory Center.

Official Title
-----------------
Barriers to Efficient PACU Discharge at a Major Academic Orthopaedic Ambulatory Surgery Center

Conditions
-----------------
Achilles Tendon Rupture, Database

Intervention / Treatment
-----------------
* Other: Chart Review


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients (18 years and older) undergoing ambulatory foot and ankle surgery Exclusion Criteria: n/a

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Achilles Tendon Rupture<br>This is a retrospective chart review to determine the etiologies contributing to prolonged PACU discharge at a major Orthopedic Ambulatory Surgical Center. | Other: Chart Review<br>* This is a retrospective chart review to determine the etiologies contributing to prolonged PACU discharge at a major Orthopedic Ambulatory Surgical Center.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time required for discharge | This is the length of time that patients stay in the recovery room | Day of surgery (Day 0) through discharge, average of 6 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Supplemental Analgesics | This is the amount of pain medication patients require in the recovery room | Day of surgery (Day 0) through discharge, average of 6 hours |
A STUDY BEFORE/AFTER THE IMPLEMENTATION OF AN ANTI-INFECTIOUS PRESCRIPTION AID

Study Overview
=================
Brief Summary
-----------------
Anti-infective strategy is a major public health problem. This is a before-and-after study of an anti-infectious prescription tool with a comparison of mortality at 30 days (then 3 and 6 months) between the two inclusion phases of 6 months each.

Official Title
-----------------
EVALUATION OF 30-DAY MORTALITY AFTER A VISIT TO THE LAPEYRONIE ADULT EMERGENCY DEPARTMENT OF THE CHU MONTPELLIER FOR SEPSIS OR SEPTIC SHOCK

Conditions
-----------------
Sepsis, Septic Shock

Intervention / Treatment
-----------------
* Device: Anti-infectious prescription support tool


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Major patients Sepsis or septic shock Oral consent Exclusion criteria: minor patients death before antibiotherapy care limitations pre-hospital antibiotherapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1 : Before<br>Before phase including 186 patients patients included before the implementation of the prescription support tool | Device: Anti-infectious prescription support tool<br>* implementation of a pocket notebook with current anti-infectious recommendations in the emergency department Patients were kept under surveillance for at least one hour before discharge. Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief.<br>|
| Group 2 : After<br>After phase including 185 patients patients included after the implementation of the prescription support tool | Device: Anti-infectious prescription support tool<br>* implementation of a pocket notebook with current anti-infectious recommendations in the emergency department Patients were kept under surveillance for at least one hour before discharge. Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Numbers of patient 30-day mortality | patient survival at 30 days | 30 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Adult patients, Probabilistic antibiotic therapy to be initiated
Effect of Repeated Botulinum Toxin Injection on Gait Pattern in Stroke Patients

Study Overview
=================
Brief Summary
-----------------
Chronic stroke patients exhibit gait pattern alterations which are mainly due to spasticity and treated with repetitive multifocal botulinum toxin injection(BTI). Several studies demonstrated that single BTI-session in a single muscle of paretic lower limb(LL) improved kinematic gait parameters(GP) but surprisingly none of them assessed the effects of repetitive multifocal BTI on patient's gait pattern and their duration. The aim was to evaluate the impact of repetitive multifocal BTI-sessions on GP of chronic stroke patients. To that end, gait of patients will be compared using 3D-gait analysis after 3 consecutives BTI sessions.

Detailed Description
-----------------
All the patients will be treated with BTI . These injections will be performed under electrical stimulation control ( 5mA). The dose, the number of site of injection per muscle is at the discretion of the physician according to patients' needs and physicians' routine clinical practice. The dilution the most commonly used will be 100 U for 2.5ml (XEOMIN®)

Official Title
-----------------
Effect of 3 Consecutives Botulinum Toxin Injection on Gait Pattern in Stroke Patients

Conditions
-----------------
Botulinum Toxins Injection in Stroke Patients

Intervention / Treatment
-----------------
* Other: Motion Analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >18 years a single hemispheric cerebral vascular lesion more than 6 months previously able to walk 10 meters without any assistance having benefited of at least 2 consecutive BTI sessions, second 3D gait analysis performed at least 3 months after the last BTI. Exclusion Criteria: patient's refusal to participate to the study Inability to read the selected text Inability to cooperate No affiliation to social security

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Chronic spastic stroke patients<br>Chronic spastic stroke patients treated regularly with botulinum toxin injection in lower limb muscles | Other: Motion Analysis<br>* Motion analysis is used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| kinematics gait parameters | peak knee flexion in swing phase(°) | 3h | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| spatiotemporal gait parameters | Gait velocity (m/s) | 3h | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Botulinum toxin injections, Stroke, 3D motion analysis, Gait pattern
Genetics of Aortic Stenosis: From Family Forms to the Common Forms

Study Overview
=================
Brief Summary
-----------------
The association study will compare the allele frequencies of polymorphisms of a single nucleotide (SNP) in the population of individuals with aortic stenosis compared to a control population. Patients will be included only if they are suffering from a typical form of tight and surgical tricuspid aortic stenosis. Patients will therefore only included if they are suffering from aortic stenosis, the surface is less than 1 cm² and if histological analysis or failing intraoperative findings of the surgeon showed a tricuspid aortic stenosis.

Official Title
-----------------
Genetics of Aortic Stenosis: From Family Forms to the Common Forms

Conditions
-----------------
Aortic Stenosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Criteria has reached: That patients are operated or not, they can be considered as having a degenerative aortic stenosis, patients will be diagnosed with aortic stenosis (aortic area <1 cm) without obvious cause found. criteria not met Strictly normal aortic valve by ultrasound in an over 65-year-old patient. All patients do not fit into the above two categories are considered as having an unknown phenotype and will not be used in binding assays. In particular, the presence of an aortic sclerosis or even moderate aortic regurgitation can be considered as potentially incipient form of aortic stenosis, patients with this type of anomaly will not be scanned during family analyzes. Exclusion Criteria: Patients who did not sign the consent Non degenerative aortic stenosis or for which another cause could be found. Among the most commonly found causes are: Bicuspid aortic valve Severe renal impairment Severe Hypercholesterolemia

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| identify the genetic factors involved in the occurrence of aortic stenosis |  | 36 months |
Non-invasive Glioma Characterization Through Molecular Imaging

Study Overview
=================
Brief Summary
-----------------
MRI-based sequences can provide non-invasive quantification of intratumoral 2-hydroxyglutarate (2HG) distribution and tumor cellularity in human gliomas and help guide the development of novel glioma therapies.

Detailed Description
-----------------
This is a pilot study aiming at developing and optimizing MRI-based sequences to provide non-invasive quantification of intratumoral 2-hydroxyglutarate (2HG) distribution and tumor cellularity in human gliomas and help guide the development of novel glioma therapies.

Official Title
-----------------
Pilot Study for Non-invasive Glioma Characterization Through Molecular Imaging

Conditions
-----------------
Glioma, Brain Tumor, Primary Brain Tumor, Malignant Glioma, Malignant Primary Brain Tumor

Intervention / Treatment
-----------------
* Device: 3T MRI Scanner


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults (≥18 year old) Subjects with suspected or confirmed gliomas and who will have a medically indicated biopsy or resection of his/her brain lesion. Exclusion Criteria: Adults unable to consent Individuals who are not yet adults (infants, children, teenagers) Pregnant women Patients unable to have MRI done

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: IDH-Mutant Glioma Patients<br>Patients who have suspected or confirmed gliomas and are scheduled to undergo biopsy or resection of their brain tumors will receive a 3 Tesla (3T) Magnetic Resonance Imaging (MRI) scan of their brain. | Device: 3T MRI Scanner<br>* 3T MRI Scanner providing Mega-laser sequence for single-voxel Magnetic Resonance Spectroscopy (MRS) data for 2 hydroxyglutarate (2HG) quantitation.<br>* Other names: 3 Tesla (3T) Magnetic Resonance Imaging Scanner;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 2HG Concentration via 3T MRI Scanner | 2HG concentrations as measured via 3T MRI Scanner. | Day 1 | 
| 2HG Concentration from tissue samples | 2HG concentrations as measured via patient's surgically excised tissue sample ex vivo by tissue based liquid chromatography-mass spectrometry (LC-MS) | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Isocitrate Dehydrogenase (IDH) Mutations, MRI-Based Sequencing, Non-invasive glioma characterization, Molecular Imaging
TELEMS: Feasibility of Remote Patient Visits in MS

Study Overview
=================
Brief Summary
-----------------
This trials randomizes patients with multiple sclerosis (MS, pwMS) to a remote visit (via phone or videochat) or a regular outpatient visit. Outcomes include satisfaction on the patients' and doctor's side.

Official Title
-----------------
TELE MS RCT: A Randomized Controlled Trial to Evaluate Feasibility of Remote Patient Visits in People With Multiple Sclerosis

Conditions
-----------------
Multiple Sclerosis

Intervention / Treatment
-----------------
* Other: EDSS
* Other: Discussion of symptoms, Patient reported outcome (MSIS)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: confirmed diagnosis of any type of MS own a phone/smartphone/computer informed consent Exclusion Criteria: language barriers

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Randomized controlled trial
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: conventional visit<br>Regular outpatient visit | Other: EDSS<br>* Neurological Exam - EDSS (Expanded Disability Status Scale)<br>Other: Discussion of symptoms, Patient reported outcome (MSIS)<br>* Patients will be asked about their wellbeing<br>|
| Experimental: phone visit<br>Remote visit via phone | Other: EDSS<br>* Neurological Exam - EDSS (Expanded Disability Status Scale)<br>Other: Discussion of symptoms, Patient reported outcome (MSIS)<br>* Patients will be asked about their wellbeing<br>|
| Experimental: video visit<br>Remote visit via videochat | Other: EDSS<br>* Neurological Exam - EDSS (Expanded Disability Status Scale)<br>Other: Discussion of symptoms, Patient reported outcome (MSIS)<br>* Patients will be asked about their wellbeing<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TMPQ | Telemedicine Perception questionnaire (17-85, higher scores are better) | 1 week after intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PPSM | Patient and Physician Satisfaction with monitoring (6-30, higher scores are better) | 1 week after intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
multiple sclerosis, remote visits, telemedicine, remote patient monitoring, remote monitoring
Upper Extremity Kinematics During Walking

Study Overview
=================
Brief Summary
-----------------
Our aim is to investigate the upper extremity kinematics during walking in healthy individuals.

Detailed Description
-----------------
Determination of Upper Extremity Kinematics During Walking

Official Title
-----------------
Determination of Upper Extremity Kinematics During Walking in Healthy Individuals

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Between the ages of 20 and 40 years individuals Without any medical condition that would affect gait or arm swing Exclusion Criteria: People with upper or lower limb asymmetry

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| healthy individuals<br>Volunteer healthy individuals who are between the ages of 20-40 and who do not have any medical condition to affect gait or arm swing. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Kinematic analysis | For kinematic analysis, MVN BIOMECH Awinda MTW2-3A7G6 sensors (Xsens Technologies B.V. Enschede, The Netherlands) were used. A Kalman filter (Xsens Kalman Filter, XKF) was used for 3D reconstruction of body segment position and orientation. IMU sensors were placed in accordance with the anatomical regions found in the directive issued by the International Biomechanics Association. Joint kinematic data of bilateral upper limb, lower limb and trunk were recorded with IMU sensors and wireless station. Xsens MVN Studio 4.6 was used to track IMU orientations according to the world-based coordinate framework. To make an effective analysis, gloves, vests and velcro were used to attach sensors to the extremities and body. | up to 20 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time-Distance Characteristics of the Gait | GAITRite (CIR System INC. Clifton, NJ 07012) walkway system will be used. GAITRite; It is an electronic walkway which consists of portable carpet and sensors embedded on the carpet and transfers every foot contact to the computer when individuals walk on the carpet. With GAITRite, base of support (cm), velocity (cm / s) and cadence (steps / min) parameters will be evaluated. | up to 20 weeks |
Study of NMB (Company's Name) Drug Ejecting Balloon for Arteriovenous Fistulae

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to demonstrate the safety and effectiveness of the use of NMB's percutaneous transluminal angioplasty (PTA) Balloon.

Official Title
-----------------
The Use of NMB Drug Ejecting Balloon for Arteriovenous (AV) Dialysis Fistulae

Conditions
-----------------
Obstructive Lesions of Arteriovenous Dialysis Fistulae

Intervention / Treatment
-----------------
* Device: PTA Balloon catheter with paclitaxel
* Procedure: Plain Balloon angioplasty (PBA)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients 18 years and older Patients with arteriovenous fistula with obstructive lesion Patient who is willing and able to sign a written informed consent Exclusion Criteria: age < 18 female with child bearing potential Previous participation in another study with any investigational drug or device within the past 30 days Life expectancy of less than 12 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: NMB's PTA Balloon catheter with paclitaxel<br> | Device: PTA Balloon catheter with paclitaxel<br>* patients treated by the NMB's PTA Balloon catheter with paclitaxel<br>|
| Active Comparator: Standard Angioplasty Balloon<br> | Procedure: Plain Balloon angioplasty (PBA)<br>* PBA<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Restenosis Rate |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Restenosis rate |  | 1,3 and 12 months | 
| Easy insertion and removal |  | intraprocedural | 
| Major adverse events |  | intraprocedural, 1, 3, 6 and 12 months |